Despite many recent advances in therapy, there is still no plateau in overall survival curves in multiple myeloma. Bispecific antibodies are a novel immunotherapeutic approach designed to bind antigens on malignant plasma cells and cytotoxic immune effector cells. Early-phase clinical trials targeting B-cell maturation antigen (BCMA), GPRC5D, and FcRH5 have demonstrated a favorable safety profile, with mainly low-grade cytokine release syndrome, cytopenias, and infections. Although dose escalation is ongoing in several studies, early efficacy data show response rates in the most active dose cohorts between 61% and 83% with many deep responses; however, durability remains to be established. Further clinical trial data are eagerly anticipated.
CITATION STYLE
Lancman, G., Sastow, D. L., Cho, H. J., Jagannath, S., Madduri, D., Parekh, S. S., … Chari, A. (2021, September 1). Bispecific Antibodies in Multiple Myeloma: Present and Future. Blood Cancer Discovery. American Association for Cancer Research Inc. https://doi.org/10.1158/2643-3230.BCD-21-0028
Mendeley helps you to discover research relevant for your work.